Abstract
The Ku70/80 heterodimer is the regulatory subunit of the DNA-dependent protein kinase (DNA-PK) and its DNA-binding activity mediates DNA double-strand breaks repair. Although Ku80 was recently proposed as a caretaker gene involved in the control of genome integrity, no data are available on Ku70/80 DNA-binding activity in human tumors. Heterodimer DNA-binding activity and protein expression were assayed by electrophoretic-mobility-shift-assay (EMSA) and Western blot analysis, in nuclear and cytoplasmic extracts from eight breast, seven bladder primary tumors and three metastatic nodes from breast cancers. Corresponding normal tissues of the same patients were used as controls. Ten out of 15 tumors showed nuclear Ku-binding activity 3–10 times higher than in the normal tissues, irrespective of bladder or breast origin. Conversely, in 5/15 primary tumors and in all the metastatic nodes analysed, nuclear Ku-activity was 1.5–4.5-fold lower than in the corresponding normal tissues. Cytoplasmic heterodimer activity significantly differed between tumor and normal tissues, displaying a 2–10-fold increase in neoplastic tissues. Three different patterns combining both Ku expression and activity with tumor characteristics were identified. In low aggressive breast tumors p70/p80 proteins were expressed in tumor but not in normal tissues. The heterodimer binding-activity matched the protein levels. In non-invasive bladder carcinomas no significant differences in protein expression between tumor and the corresponding normal tissues were found, however heterodimer binding-activity was increased in tumor samples. In breast and bladder tumors, at the advanced stage and in node metastases, the binding activity was strongly reduced in tumor biopsies, however no differences were demonstrated between normal and tumor protein levels. Our results suggest a different modulation of Ku70/80 DNA-binding activity in human neoplastic tissues, possibly related to tumor progression. Findings provide further data on tissue-specific protein expression and post-translational regulation of heterodimer activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J and Kumar R. . 1998 J. Biol. Chem. 273: 1568–1573.
Berwick M and Vineis P. . 2000 J. Natl. Cancer Inst. 92: 874–897.
Bogue M and Roth DB. . 1996 Curr. Opin. Immunol. 8: 175–180.
Chu G. . 1997 J. Biol. Chem. 272: Z4097–Z4100.
Cordon-Cardo C. . 1998 Cancer Surv. 32: 115–131.
Dahiya R and Deng G. . 1998 Cancer Res. Treat. 52: 185–200.
Dalziel RG, Mendelson SC and Quinn JP. . 1992 Autoimmunity 13: 265–267.
De Vita R, Forte D, Maggi F, Eleuteri P and Di Silverio F. . 1991 Eur. Urol. 19: 65–73.
Difilippantonio MJ, Zhu J, Chen HT, Meffre E, Nussenzweig MC, Max EE, Ried T and Nussenzweig A. . 2000 Nature 404: 510–514.
Dignam JD, Lebovitz RM and Roeder RG. . 1983 Nucleic Acids Res. 11: 1475–1489.
Fearon ER and Vogelstein B. . 1990 Cell 61: 759–767.
Frasca D, Barattini P, Goso C, Pucci S, Rizzo G, Bartoloni C, Costanzo M, Errani A, Guidi L, Antico L, Tricerri A and Doria G. . 1998 Mech. Ageing Dev. 100: 197–208.
Gottlieb TM and Jackson SP. . 1993 Cell 72: 131–142.
Hwang BJ, Smider V and Chu G. . 1999 Methods Mol. Biol. 113: 103–120.
Jackson SP and Jeggo PA. . 1995 Trends Biochem. Sci. 20: 412–415.
Jhappan C, Morse HC, Fleishmann RD, Gottesman MM and Merlino G. . 1997 Nature Genetics 17: 483–486.
Jin S and Weaver D. . 1997 EMBO J. 16: 6874–6885.
Jin SF, Inoue S and Weaver DT. . 1997 Cancer Surv. 29: 221–261.
Kessel D. . 1994 In Vivo 8: 829–834.
Kinsella AR, Smith D and Pickard M. . 1997 Br. J. Cancer 75: 935–945.
Kinzler KW and Vogelstein B. . 1997 Nature 386: 761–763.
Koike M, Awaji T, Kataoka M, Tsujimoto G, Kartasova T, Koike A and Shiomi T. . 1999 J. Cell. Sci. 112: 4031–4039.
Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C and Thomas-Tsagli E. . 1997 Pathol. Res. Pract. 193: 767–775.
Le Romancer M, Reyl-Desmars F, Cherifi Y, Pigeon C, Bottari S, Meyer O and Lewin MJ. . 1994 J. Biol. Chem. 269: 17464–17468.
Li GC, Ouyang H, Li X, Nagasawa H, Little JB, Chen DJ, Ling CC, Fuks Z and Cordon-Cardo C. . 1998 Mol. Cell. 2: 1–8.
Loeb KR and Loeb LA. . 2000 Carcinogenesis 21: 379–385.
Mimori T and Hardin JA. . 1986 J. Biol. Chem. 261: 2274–2278.
Moll U, Lau R, Sypes MA, Gupta MM and Anderson CW. . 1999 Oncogene 18: 3114–3126.
Morgan WF and Murnane JP. . 1995 Cancer Metastasis Rev. 14: 49–58.
Nussenzweig A, Sokol K, Burgman P, Li L and Li GC. . 1997 Proc. Natl. Acad. Sci. USA 94: 13588–13593.
O'Neill KL, McKelvey VJ, Hoper M, Monteverde H, Odling-Smee GW, Logan H, Abram WP and McKenna PG. . 1992 Med. Lab. Sci. 49: 244–247.
Powell SN and Abraham EH. . 1993 Cytotechnology 12: 325–345.
Prabhakar BS, Allaway GP, Srinivasappa J and Notkins AL. . 1990 J. Clin. Invest. 86: 1301–1305.
Sato T, Akiyama F, Sakamoto G, Kasumi F and Nakamura Y. . 1991 Cancer Res. 51: 5794–5799.
Sekowsky JW, Malkas LH, Schnaper L, Bechtel PE, Long BJ and Hickey RJ. . 1998 Cancer Res. 58: 3259–3263.
Teoh G, Urashima M, Greenfield EA, Nguyen KA, Lee JF, Chauhan D, Ogata A, Treon SP and Anderson KC. . 1998 J. Clin. Invest. 101: 1379–1388.
Tovari J, Szende B, Bocsi J, Falaschi A, Simoncsits A, Pongor S, Erchegyi J, Stetak A and Keri G. . 1998 Cell Signal 10: 277–282.
Wang J, Dong X and Reeves WHJ. . 1998 J. Biol. Chem. 273: 31068–31074.
Wong SW, Rangan AM, Bilous AM, Boyages J, Gebski V and Benson EM. . 1999 Pathology 31: 90–94.
Yang CR, Yeh S, Leskov K, Odegaard E, Hsu HL, Chang C, Kinsella TJ, Chen DJ and Boothman DA. . 1999 Nucleic Acids Res. 27: 2165–2174.
Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ and Boothman DA. . 2000 Proc. Natl. Acad. Sci. USA 97: 5907–5912.
Yoo S and Dynan WS. . 1998 Biochem. 37: 1336–1343.
Zhang WW and Yaneva M. . 1992 Biochem. Biophys. Res. Commun. 186: 574–579.
Acknowledgements
This work was partly supported by grant IRCCS/RC/1999 from the Italian Ministry of Health.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pucci, S., Mazzarelli, P., Rabitti, C. et al. Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene 20, 739–747 (2001). https://doi.org/10.1038/sj.onc.1204148
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204148
Keywords
This article is cited by
-
Cisplatin-induced cell death increases the degradation of the MRE11-RAD50-NBS1 complex through the autophagy/lysosomal pathway
Cell Death & Differentiation (2023)
-
The Ku complex: recent advances and emerging roles outside of non-homologous end-joining
Cellular and Molecular Life Sciences (2021)
-
Overexpression of CLC-3 is regulated by XRCC5 and is a poor prognostic biomarker for gastric cancer
Journal of Hematology & Oncology (2018)
-
RETRACTED ARTICLE: Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma
Cell Death & Disease (2016)
-
Comparison of cytotoxicity and genotoxicity of 4-hydroxytamoxifen in combination with Tualang honey in MCF-7 and MCF-10A cells
BMC Complementary and Alternative Medicine (2014)